DHEA Supplementation: Evidence-Based Guide to Anti-Aging and Hormone Health

At a Glance

DHEA (dehydroepiandrosterone) holds the distinction of being the most abundant circulating steroid hormone in the human body—yet it remains one of the least discussed in mainstream clinical practice. Produced primarily by the zona reticularis of the adrenal cortex, DHEA serves as the principal precursor to both androgens and estrogens — itself synthesized downstream of pregnenolone, the master steroid hormone precursor from which the entire steroidogenic cascade originates. Its precipitous age-related decline—steeper than virtually any other hormone—positions it as a compelling target in evidence-based longevity medicine.

In my clinical experience working with patients across aging, chronic illness, and performance optimization, low DHEA-S (the stable sulfated storage form measured in blood) consistently correlates with fatigue, impaired immune resilience, reduced bone density, and blunted stress tolerance. Restoring levels to a physiological young-adult range—not supraphysiological—is the therapeutic goal. This guide covers the science, who benefits, dosing strategy, and the safety considerations that make careful lab monitoring non-negotiable.

Why DHEA Declines and Why It Matters

The Adrenopause Curve

Unlike cortisol, which remains relatively stable across decades, DHEA follows a strikingly different trajectory. Peak serum DHEA-S in both men and women occurs between ages 20–25, averaging 300–500 µg/dL in men and 200–350 µg/dL in women. By age 70–80, values typically fall to 50–100 µg/dL—an 80% or greater reduction spanning five decades.

This phenomenon is sometimes called adrenopause, and it unfolds independently of gonadal hormone changes. A 65-year-old may have testosterone or estradiol levels that have declined modestly with appropriate hormone optimization, yet DHEA-S has often dropped catastrophically without any clinical attention.

DHEA as a Precursor Hormone

DHEA doesn’t act exclusively as a direct agonist at receptor sites—its most significant role is as a prohormone substrate. Peripheral tissues (skin, bone, muscle, brain, immune cells) convert DHEA into testosterone, estradiol, androstenedione, and 7-alpha-hydroxy-DHEA depending on local enzymatic activity. This means DHEA supplementation effectively raises the “raw material” pool from which tissues synthesize the sex hormones they need locally, without the systemic surge of direct testosterone or estradiol administration.

This peripheral conversion model has practical implications: DHEA supplementation tends to produce gentler, more tissue-specific hormonal effects than exogenous sex hormone therapy, with correspondingly more manageable safety profiles in most patients.

Neurosteroid Activity

Beyond its precursor role, DHEA and its sulfated form DHEA-S function as neurosteroids—bioactive compounds synthesized in the brain and exerting direct modulatory effects on GABA-A receptors (antagonistic) and NMDA receptors (potentiating). This explains the cognition-relevant effects observed in trials: DHEA increases excitatory tone in circuits associated with learning, memory consolidation, and mood regulation. Low DHEA-S is consistently associated with greater depressive symptom burden in epidemiological data, independent of sex hormone status.

Clinical Evidence: What the Research Actually Shows

Bone Density

One of the most replicated findings in DHEA supplementation research involves skeletal effects. A landmark two-year double-blind RCT by Jankowski et al. (2006, JCEM) demonstrated significant increases in spine and hip bone mineral density in older adults receiving 50 mg/day DHEA compared to placebo. Subsequent meta-analyses have generally confirmed modest but meaningful positive effects on BMD, particularly in postmenopausal women and older men with low baseline DHEA-S.

The mechanism is multi-factorial: local conversion to estradiol in osteoblasts reduces resorption, while androgenic effects stimulate bone formation. This makes DHEA one of the few single agents with dual anabolic-antiresorptive potential on bone.

Cognitive Function and Neuroprotetion

The data on cognition are more heterogeneous but clinically suggestive. A 2006 randomized crossover trial (Neuropsychopharmacology) found that 50 mg/day DHEA for 6 weeks significantly improved declarative memory performance compared to placebo in older adults. Multiple shorter trials have demonstrated improvements in verbal learning and executive function.

Of particular relevance to my chronic illness patient population: DHEA-S levels are frequently depressed in patients with long-term infections, post-COVID syndrome, and mold-related illness—conditions associated with chronic HPA axis dysregulation. In these patients, restoring DHEA appears to improve cognitive clarity as part of a broader hormone-optimization strategy, though disentangling DHEA-specific effects from other interventions is methodologically difficult in clinical practice.

Immune Modulation

DHEA exerts significant immunomodulatory effects, generally shifting immune activity toward Th1 (cellular immunity) while buffering excessive inflammatory cytokine production. Animal data are compelling: adrenalectomized (DHEA-depleted) animals show dramatically increased susceptibility to viral and bacterial infections, restored to normal with DHEA replacement.

Human data show that supplementation increases natural killer cell activity, augments IL-2 production, and improves vaccine responses in older adults—a clinically meaningful finding given age-related immune senescence. For patients with chronic infections or immunodeficiency states, addressing DHEA deficiency is part of a comprehensive immune-support protocol.

Body Composition

DHEA’s androgenic conversion promotes lean mass preservation and modest fat redistribution, particularly targeting visceral adiposity. While effects are smaller than direct testosterone replacement, a meta-analysis of RCTs (Obesity Reviews, 2013) found statistically significant reductions in trunk fat percentage with DHEA supplementation at doses of 50–100 mg/day in older adults. These effects are more pronounced in patients with lower baseline DHEA-S levels.

Adrenal Resilience and Stress Response

DHEA and cortisol are produced in adjacent adrenal zones and exist in a regulatory balance. Under chronic stress, HPA activation preferentially sustains cortisol output while DHEA production is relatively suppressed—a pattern that shifts the DHEA:cortisol ratio downward. This ratio is an underappreciated clinical biomarker: low DHEA:cortisol correlates with burnout, inflammatory load, impaired recovery, and immune vulnerability.

In patients presenting with chronic fatigue, I routinely measure a morning DHEA-S alongside cortisol awakening response. Correcting DHEA deficiency in the context of HPA dysregulation is typically one component of a multi-modal recovery protocol, not a standalone fix.

Who Is a Candidate for DHEA Supplementation?

Not everyone with declining DHEA-S needs supplementation. The clinical decision involves balancing documented deficiency against individual risk factors. Strong candidates include:

• Serum DHEA-S below age-adjusted reference range, with corroborating symptoms (fatigue, cognitive fog, low libido, poor bone density trend)
• Post-menopausal women with confirmed deficiency, particularly those unable or unwilling to use conventional HRT and seeking targeted bone/mood support
• Older men (55+) with low DHEA-S, low-normal testosterone, and body composition concerns
• Patients with chronic HPA dysfunction (post-COVID, chronic Lyme, mold illness, adrenal burnout) where DHEA:cortisol ratio is suppressed
• Autoimmune or immunodeficient patients where NK cell and Th1 support is clinically indicated

Relative contraindications include hormone-sensitive malignancies (breast, prostate, ovarian), active polycystic ovarian syndrome, and patients with androgenic side effects from prior hormone therapy. These require individual risk-benefit discussion.

Dosing, Forms, and Timing

Oral DHEA

The most studied and convenient form. Standard physiological-replacement dosing:

• Women: 10–25 mg/day (lower end is often sufficient given greater androgenic sensitivity)
• Men: 25–50 mg/day
• Older adults (70+): Start at 10–15 mg and titrate with labs

Take in the morning, ideally with food. Adrenal DHEA production follows a morning-dominant circadian rhythm; morning dosing respects this pattern and minimizes the small theoretical risk of disrupting sleep (via stimulatory neurosteroid effects at GABA receptors).

Transdermal DHEA

Cream or gel formulations at 10–25 mg/day applied to thin skin (inner forearm, inner thigh). Transdermal delivery bypasses first-pass hepatic metabolism and may shift the conversion ratio toward DHT and estradiol relative to oral dosing—relevant for patients seeking more androgenic or estrogenic effects. Less predictable serum levels than oral formulations; requires monitoring DHEA-S rather than relying on dose alone.

Vaginal DHEA (Intrarosa)

FDA-approved 0.5% DHEA vaginal insert (prasterone) for dyspareunia in postmenopausal women. Delivers DHEA locally to vaginal epithelium with minimal systemic absorption, producing localized estrogenic and androgenic effects. This represents the clearest regulatory pathway and is well-supported by phase III trial data.

What to Avoid

Supraphysiological dosing (>100 mg/day in non-supervised settings) substantially increases androgenic side effects: acne, oily skin, hair thinning in women, and the potential for unwanted estrogen conversion. The goal is always to restore—not to exceed—young-adult reference ranges.

Monitoring: Lab Testing Protocol

DHEA supplementation should never proceed without baseline labs and periodic follow-up. My standard protocol:

Baseline (before starting):

• Serum DHEA-S
• Total and free testosterone
• Estradiol (E2)
• Sex hormone binding globulin (SHBG)
• PSA (men over 45)
• Cortisol (morning, ideally with cortisol awakening response)

Follow-up at 6–8 weeks post-initiation:

• DHEA-S (target: mid-range for 25–35 year age group)
• Testosterone and estradiol (ensure no unwanted elevation)

Ongoing every 3–6 months while on supplementation.

The target DHEA-S range is not “normal for age”—low-normal for a 70-year-old is still significantly deficient. The aim is physiological restoration toward levels seen in healthy young adults, typically 200–350 µg/dL for women and 300–500 µg/dL for men, guided by clinical response and absence of side effects.

Side Effects and Safety Considerations

At physiological doses with appropriate lab monitoring, DHEA is generally well-tolerated. Documented adverse effects are dose-dependent and reversible:

Androgenic effects (more common in women at higher doses): Acne, increased facial/body hair, oily skin, changes in voice (rare, at high doses). These signal excessive androgenic conversion and prompt dose reduction.

Estrogenic effects: Breast tenderness, fluid retention, mood changes. More common in individuals with high aromatase activity (often correlating with excess adiposity). Monitor estradiol.

Interactions: DHEA can modestly increase the activity of insulin and improve insulin sensitivity—a generally favorable effect but one to note in patients on hypoglycemic medications. Theoretical interaction with corticosteroid medications via shared adrenal substrate competition.

The cancer question: The relationship between DHEA and hormone-sensitive cancers is the most clinically important safety consideration. Current evidence does not demonstrate that physiological-dose DHEA supplementation increases cancer risk in healthy individuals. However, DHEA is absolutely contraindicated in patients with active or recent hormone-sensitive cancers (ER+/PR+ breast cancer, prostate cancer) until further evidence clarifies safety in these populations. This is not a theoretical concern to dismiss—it requires direct clinical judgment case-by-case.

DHEA in the Context of a Longevity Protocol

Isolated DHEA supplementation rarely addresses the full picture in aging or chronic illness. In my practice, DHEA assessment is embedded in a comprehensive hormone and metabolic evaluation that considers:

• Thyroid function (hypothyroidism suppresses DHEA production independently)
• Insulin resistance (metabolic dysfunction accelerates DHEA decline and impairs conversion)
• Sleep quality (deep sleep is the primary driver of growth hormone and steroid hormone restoration)
• Mitochondrial function (steroidogenesis is an energy-intensive process; mitochondrial dysfunction blunts it)
• Micronutrient status (zinc, vitamin D, magnesium, and B5 are rate-limiting cofactors in steroid biosynthesis)

For patients with a low DHEA-S on functional medicine labs, addressing these upstream factors often produces partial spontaneous recovery—sometimes reducing or eliminating the need for direct supplementation. When DHEA remains low despite optimization of these foundations, targeted supplementation becomes appropriate.

Related Articles

• Functional Medicine Labs: What to Test and Why — includes DHEA-S in the core hormone panel and explains how to interpret results in the clinical context of aging and chronic illness.
• CoQ10 and Heart Health: Mitochondria and Cardiovascular Protection — mitochondrial health and steroidogenesis are closely linked; addressing both together is more effective than either alone.
• Ashwagandha and Cortisol: Adaptogen Evidence Review — DHEA and cortisol work in concert as adrenal hormones; ashwagandha modulates the HPA axis and may complement DHEA restoration.
• Longevity Hormone Optimization — comprehensive overview of age-related hormone decline including testosterone, estrogen, growth hormone, and thyroid alongside DHEA.
• Rapamycin for Longevity: Evidence and Protocol — for patients pursuing multi-modal longevity interventions where DHEA optimization is one component of a broader protocol.

References

1. Jankowski CM, et al. “Effects of dehydroepiandrosterone replacement therapy on bone mineral density in older adults: a randomized, controlled trial.” J Clin Endocrinol Metab. 2006;91(8):2986–2993. PMID: 16720656
2. Wolkowitz OM, et al. “Double-blind treatment of major depression with dehydroepiandrosterone.” Am J Psychiatry. 1999;156(4):646–649. PMID: 10200753
3. Nair KS, et al. “DHEA in elderly women and DHEA or testosterone in elderly men.” N Engl J Med. 2006;355(16):1647–1659. PMID: 17050889
4. Villareal DT, Holloszy JO. “Effect of DHEA on abdominal fat and insulin action in elderly women and men.” JAMA. 2004;292(18):2243–2248. PMID: 15536111
5. Straub RH, Scholmerich J, Zietz B. “Replacement therapy with DHEA plus corticosteroids in patients with chronic inflammatory diseases.” Z Rheumatol. 2000;59 Suppl 2:II/108-18. PMID: 11155093
6. Labrie F, et al. “Intracrinology and the skin.” Horm Res. 2000;54(5-6):218–229. PMID: 11595809
7. Elraiyah T, et al. “Clinical review: The benefits and harms of systemic dehydroepiandrosterone (DHEA) in postmenopausal women with normal adrenal function.” J Clin Endocrinol Metab. 2014;99(10):3536–3542. PMID: 25279572